Auriant Mining AB (publ.) announces departure of Denis

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Auriant Mining AB (publ.) announces departure of Denis Alexandrov, updates on Chukotka Management Contract and announces preliminary 2015 production results

Highlights:

·         In 2015 Tardan gold production increased by 21% and amounted to 817 kg (26,267 oz)

·         An average gold grade at Tardan during 2015 was 3.03 g/t which is 76% increase, comparing to 2014 grades

·         Denis Alexandrov is leaving the company on January 15 th

·         Sergey Ustimenko is appointed as CEO of Auriant Mining AB

·         Chukotka management contract will be terminated by mutual agreement effective from January 18 th

2015 Production Update

Auriant Mining has achieved its production target at Tardan and produced 817 kg of hard rock gold, which is 21% more than in 2014.  Average 2015 grade at Tardan was 3.03 g/t compared to 1.72 g/t in 2014, an increase of 76%. This improvement in grade and the re-launch of the gravitational plant has allowed the company to increase Tardan’s production in 2015 and reduce costs. 

Auriant plans further increase in grades in 2016 up to 20% and correspondingly increase in production, which is expected to reach 1 tonne.

We continue to work on development of Kara-Beldyr project.  In first half of 2016 we expect to have reserve calculation approved by GKZ (Russian State Reserve Committee) and after that to start design of the mine and the plant.

Change in management

Auriant announces that Denis Alexandrov, who has been CEO since May 2012, will leave the company on January 15 th .

Commenting, Lord Daresbury, Chairman of Auriant Mining, said: “Auriant thanks Denis for the great job he has done.  Under his leadership the company has come a long way.  We wish him every success in his new project”.

Sergey Ustimenko has been appointed CEO of the company.  Sergey joined Auriant in May 2014 as CFO.  He is a fully qualified CPA (2001) and has extensive financial and accounting experience.  He held CFO positions in large Russian and international companies engaged in the sales and service of machines and equipment, airline industry and financial services. Prior to this Sergey was financial controller at LUKOIL, the largest private Russian oil company. He also has 7 years’ experience as an auditor with BDO, KPMG and Arthur Andersen.

Alexander Buchnev will take the position of acting CFO.  Alexander has worked for Auriant since February 2013.  He is a fully qualified ACCA and has extensive finance experience: he has worked for 10 years for leading auditing and advisory companies, including 8 years with Ernst & Young.

The change in the management will not have negative effect on Auriant’s overhead costs neither on the level of holding company, Auriant Mining AB, nor on the consolidated level.

Following termination of Mr. Alexandrov’s employment with the Company, his 556,326 vested stock options 2012/2017 series III (with strike price SEK 15) will remain exercisable until 1 June 2017.  Mr. Alexandrov’s other vested stock options, including 46,666 stock options 2013/2018 series I (with strike price SEK 15) and 30,000 stock options 2014/2019 series I (with strike price SEK 5.85) will remain exercisable during 6 months, i.e. until 16 July 2016, but not later.   Furthermore, 92,721 warrants 2012/2017 series I and 92,721 warrants 2012/2017 series II will remain exercisable during the period from 1 June 2016 until 1 June 2017 at a strike price of SEK 250.  All other Mr. Alexandrov’s stock options and warrants will expire with immediate effect.

Update on Chukotka Management Contract

Auriant announces that effective from January 18 th the Chukotka Management Contract (an agreement to manage and develop Valunisty Mine LLC and Kanchalano-Amguemskaya Square LLC (KAP)) is terminated by mutual agreement.  Auriant will be paid $2 100 000 under the termination agreements, including  compensation for termination.  The total amount of fee income earned by Auriant under the agreement in 2015 amounts to US$ 3.6 mln.

For more information, please contact:

Peter Daresbury, Chairman on the Board

Tel: + 44 194 886 1900

e-mail: peter.daresbury@daresburyltd.co.uk

 

 

Sergey Ustimenko, CEO

tel: +7 495 660 22 20

e-mail: sergey.ustimenko@auriant.com

 

 

Company name: Auriant Mining AB

Short name: AUR

ISIN-code: SE0001337213

 

Website: www.auriant.com Twitter: @auriantmining

 

 

Auriant Mining AB (AUR) is a Swedish junior mining company focused on gold exploration and production in Russia, primarily in Zabaikalye and the Republics of Khakassia and Tyva. The company has currently four assets, including two operating mines (Tardan and Solcocon) one early stage exploration asset and one development asset. The group’s mineral licenses are estimated to contain official Russian State Reserves Committee (GKZ) reserves of 829 500, 000 troy ounces (1 oz = 31.1 g) in the C1 and C2 categories and 500,000 troy ounces in NI 43-101 standard.

Since July 19, 2010, Auriant Mining´s shares are traded on First North Premier at the NASDAQ OMX Nordic Exchange under the short name AUR . For more information please visit www.auriant.com. Mangold Fondkommission is Certified Adviser to Auriant, for more information please call +46 8 503 015 50 or visit www.mangold.se.

Cautionary Statement: Statements and assumptions made in this report with respect to Auriant Mining AB’s (“AUR”) current plans, estimates, strategies and beliefs, and other statements that are not historical facts, are forward-looking statements about the future performance of AUR. Forward-looking statements include, but are not limited to, those using words such as "may", "might", "seeks", "expects", "anticipates", "estimates", "believes", "projects", "plans", strategy", "forecast" and similar expressions. These statements reflect management's expectations and assumptions in light of currently available information. They are subject to a number of risks and uncertainties, including, but not limited to, (i) changes in the economic, regulatory and political environments in the countries where AUR operates; (ii) changes relating to the geological information available in respect of the various projects undertaken; (iii) AUR’s continued ability to secure enough financing to carry on its operations as a going concern; (iv) the success of its potential joint ventures and alliances, if any; (v) exchange rates, particularly between the Russian rouble and the U.S. dollar. In the light of the many risks and uncertainties surrounding any gold production and exploration company at an early stage of its development, the actual results could differ materially from those presented and forecast in this report. AUR assumes no unconditional obligation to immediately update any such statements and/or forecasts

This press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action as a  whole or in part is subject to legal restrictions. Nothing in this press release should be considered as an offer to invest or otherwise trade in shares of Auriant Mining AB (publ). The proposed issue will not be directed at residents or those living in the United States, Australia, Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action would require further prospectus, other offering documentation, registration or other measures beyond those required by Swedish law. No securities will be registered under the United States Securities Act of 1933, a similar law in any state in the United States, or under any provincial law in Canada, nor under the applicable law of another country.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 8

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading

Top 5 Most Recently Viewed Articles

HeartCore's Journey: From Nasdaq Challenges to Growth Potential

Updated Category News Views 35

HeartCore's Nasdaq Delisting Challenge HeartCore Enterprises, Inc. (NASDAQ:HTCR), a provider of enterprise software and consulting services, is currently facing a significant challenge related to its listing on the Nasdaq Capital Market. The company has received notice of non-compliance with the minimum bid price requirement, which mandates that its stock price must be at...

Continue Reading
Mitchell Capital Expands Portfolio with Optelos Acquisition

Updated Category News Views 236

Mitchell Capital's New Acquisition of Optelos Mitchell Capital, a prominent private equity firm, recently announced a significant acquisition that marks a pivotal moment for their long-term investment strategy. They have secured a controlling interest in Optelos, a distinguished provider of digital twin platforms that are tailored for enhancing critical infrastructure...

Continue Reading
Tampa Bay Lightning and Scripps Sports Forge Exciting Partnership

Updated Category News Views 247

Partnership Announcement Between Tampa Bay Lightning and Scripps Sports The Tampa Bay Lightning have officially entered into an exciting multi-year partnership with Scripps Sports. This collaboration signifies a new chapter for the Tampa Bay Lightning, expanding their reach in broadcasting and enhancing viewer engagement with National Hockey League (NHL) games. Through...

Continue Reading
Kazia Therapeutics Sets Meeting with FDA on Glioblastoma Treatment

Updated Category News Views 61

Kazia Therapeutics Prepares for FDA Meeting on Paxalisib Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is set to meet with the U.S. Food and Drug Administration (FDA) to explore potential pathways for the registration of its innovative drug, Paxalisib, aimed at treating newly diagnosed glioblastoma multiforme (GBM). This crucial...

Continue Reading
Important Notice for Flux Power Investors on Lead Plaintiff Claims

Updated Category News Views 100

Overview of Flux Power Investor Claims Investors with concerns regarding their investments in Flux Power Holdings, Inc. (NASDAQ: FLUX) have much to consider as recent developments unfold. The national securities law firm, Faruqi & Faruqi, LLP, is actively investigating claims that could impact investor interests and is eager to assist those affected. Critical Investment...

Continue Reading